» Articles » PMID: 22772667

5-HT2 Receptor Distribution Shown by [18F] Setoperone PET in High-functioning Autistic Adults

Overview
Specialties Neurology
Psychiatry
Date 2012 Jul 10
PMID 22772667
Citations 17
Authors
Affiliations
Soon will be listed here.
Abstract

The serotonergic system is implicated in disordered emotional behavior. Autism is characterized by impaired processing of emotional information. The serotonergic (5-HT) system is also critically involved in brain development, and abnormal brain synthesis of serotonin is observed in autism. Furthermore, whole blood and platelet serotonin have been reported to be elevated in autism. The authors examined the CNS serotonin system in autism in vivo. 5-HT2 receptors were visualized by PET imaging of [18F]setoperone-binding in this pilot study of 6 high-functioning autistic adults and 10 matched-control participants. Autism subjects had less thalamic [18F]setoperone binding than controls, when covaried for age, but no difference reached significance in other areas. A negative relationship between thalamic binding and history of language impairment was also observed. Further studies will be needed to gain a clearer picture of the role of the 5-HT system in autism.

Citing Articles

C-UCB-J PET imaging is consistent with lower synaptic density in autistic adults.

Matuskey D, Yang Y, Naganawa M, Koohsari S, Toyonaga T, Gravel P Mol Psychiatry. 2024; .

PMID: 39367053 DOI: 10.1038/s41380-024-02776-2.


Resting-State Functional MRI and PET Imaging as Noninvasive Tools to Study (Ab)Normal Neurodevelopment in Humans and Rodents.

Millevert C, Vidas-Guscic N, Vanherp L, Jonckers E, Verhoye M, Staelens S J Neurosci. 2023; 43(49):8275-8293.

PMID: 38073598 PMC: 10711730. DOI: 10.1523/JNEUROSCI.1043-23.2023.


Neuroimaging genetics approaches to identify new biomarkers for the early diagnosis of autism spectrum disorder.

Nisar S, Haris M Mol Psychiatry. 2023; 28(12):4995-5008.

PMID: 37069342 PMC: 11041805. DOI: 10.1038/s41380-023-02060-9.


Editorial: Precision medicine approaches for heterogeneous conditions such as autism spectrum disorders (The need for a biomarker exploration phase in clinical trials - Phase 2m).

Beversdorf D, Anagnostou E, Hardan A, Wang P, Erickson C, Frazier T Front Psychiatry. 2023; 13:1079006.

PMID: 36741580 PMC: 9893852. DOI: 10.3389/fpsyt.2022.1079006.


Serotonin Receptors as Therapeutic Targets for Autism Spectrum Disorder Treatment.

Lee A, Choo H, Jeon B Int J Mol Sci. 2022; 23(12).

PMID: 35742963 PMC: 9223717. DOI: 10.3390/ijms23126515.